Abstract

Acadia Healthcare is scheduled to release its fiscal first-quarter results on April 29, 2026 Post Market, with investors looking for revenue around 822.92 million US dollars and adjusted EPS near 0.27, and with market attention concentrated on expense discipline, liability-cost normalization, and the pace of top-line growth.

Market Forecast

Consensus tracking indicates Acadia Healthcare’s current-quarter revenue at approximately 822.92 million US dollars, implying 6.89% year-over-year growth, with adjusted EPS estimated at 0.27, down 25.44% year over year; EBIT is projected at about 75.96 million US dollars, a 9.80% year-over-year decline. There is no explicit market forecast for gross margin or net margin, so the focus remains on revenue, earnings cadence, and the conversion of EBIT to adjusted EPS within the company’s guidance range. The core business is expected to sustain mid‑single‑digit revenue growth, supported by bed additions and stable volumes, while outcomes this quarter will hinge on price/mix and controllable operating expenses. Medicaid-funded programs remain the largest and most durable revenue base, with last reported segment revenue of 1.91 billion US dollars and an expected growth trajectory broadly aligned with companywide expansion where segment-level year-over-year disclosure is unavailable.

Last Quarter Review

Acadia Healthcare delivered revenue of 821.46 million US dollars in the most recent quarter, with a gross profit margin of 40.15%, GAAP net loss attributable to shareholders of 1.18 billion US dollars, a net profit margin of −143.34%, and adjusted EPS of 0.07, down 89.06% year over year. A key financial highlight was the 6.10% revenue growth year over year to 821.46 million US dollars alongside positive EBIT of 54.10 million US dollars, even as below‑the‑line items drove a large GAAP net loss and compressed net margin. On the business side, the company’s core inpatient and residential treatment operations posted 821.46 million US dollars of revenue, up 6.10% year over year, reflecting resilient demand and contribution from recent capacity additions. Segment composition underscores the revenue base and payor dynamics: Medicaid-funded programs accounted for 1.91 billion US dollars, or 57.72% of mix; Commercial contributed 813.79 million US dollars, or 24.57%; Medicare contributed 473.46 million US dollars, or 14.29%; Self-pay added 64.82 million US dollars, or 1.96%; and Other revenue was 48.54 million US dollars, or 1.47%. While segment-level year-over-year growth was not disclosed, the mix points to a payer structure that balances exposure to public and commercial funding streams.

Current Quarter Outlook

Core operations and payor mix

Management’s near-term revenue framework, echoed by market estimates, calls for about 822.92 million US dollars this quarter, up 6.89% year over year, with adjusted EPS near 0.27 and EBIT around 75.96 million US dollars. The expected top-line expansion is consistent with the company’s earlier range of 820–830 million US dollars for the quarter and reflects the combined effect of modest volume gains and steady rate realization. The EPS forecast, down 25.44% year over year, embeds higher operating and non-operating costs, which investors will parse for sustainability as cost lines stabilize after recent spikes in professional and general liability expenses. The revenue mix remains a central determinant of margin resilience. A higher share of Commercial and Medicare days typically supports rate realization, while Medicaid increases can bolster occupancy and bed utilization but may temper rate economics depending on case acuity and state-level reimbursement. Against that backdrop, quarter-to-quarter variability in average length of stay, case mix, and referral flow can materially influence revenue per patient day and revenue per location, which in turn drives gross-margin stability relative to staffing and fixed-cost leverage. Labor remains a pivotal swing factor. Staffing availability and utilization efficiency influence both throughput and cost of care, affecting gross margin relative to the 40.15% reported last quarter. Any further normalization in overtime and agency usage, together with productivity gains in new or recently expanded facilities, would aid flow-through from revenue to EBIT and EPS. With EBIT forecast to decline 9.80% year over year despite revenue growth, the market appears to be discounting higher operating costs in the near term; upside would likely require clear evidence of cost containment and improved conversion from revenue to operating income.

Highest‑potential growth area: Medicaid-funded programs

Medicaid-funded offerings remain the largest revenue contributor at 1.91 billion US dollars on the most recent segment snapshot, representing 57.72% of mix. This footprint provides scale and volume stability, and it is often the locus for bed additions and new program launches that expand access in underserved geographies. Given the segment’s size, even modest percentage growth can deliver meaningful absolute revenue gains; where segment-level year-over-year disclosure is not available, investors generally benchmark this area against the company’s overall outlook, which implies approximately 6.89% growth for the quarter. The near-term thesis for this segment rests on the combination of occupancy recovery, new program ramp, and the impact of rate actions negotiated at the state level. Additional access points and improved referral pipelines can raise throughput, while operational leverage from maturing de novos supports incremental profitability over time. That said, revenue quality within Medicaid depends on acuity and care setting; case-mix shifts can influence reimbursement intensity and ultimately the segment’s contribution margin, making throughput, clinician staffing stability, and program mix the operational levers to watch this quarter. A sustained expansion in Medicaid-funded volumes can also create a positive network effect across other payor channels by stabilizing clinician schedules and reducing unit downtime, which improves fixed-cost absorption. The translation from volume to earnings hinges on efficiency: scheduling discipline, clinician utilization, and unit-level management are central to preserving margins, particularly as liability and insurance costs remain elevated versus historical baselines. Investors will be most attentive to whether capacity additions translate to higher same-facility revenue and steady revenue per patient day without adverse dilution to per‑unit profitability.

Key swing factors for the stock this quarter

Expense normalization is the primary earnings swing factor. The company recently indicated a significant year-over-year increase in professional and general liability costs through 2025, and the market will look for signs of stabilization in that run-rate as the year progresses. If liability-related expenses trend below the elevated assumptions that pressured recent GAAP results, conversion from EBIT to adjusted EPS could improve faster than current expectations, narrowing the gap between revenue growth and EPS contraction embedded in consensus. The second swing factor is labor and throughput. Any incremental moderation in agency hours and overtime, coupled with consistent fill rates for clinical positions, would support gross margin relative to the 40.15% level last quarter. Conversely, if staffing tightness resurfaces and necessitates premium labor, it could mute the operating leverage investors expect from mid‑single‑digit revenue growth. Monitoring revenue per patient day, occupancy, and average length of stay will provide early indications on whether revenue quality is sufficient to offset cost pressure. Finally, the cadence of program openings and bed additions will influence both near-term costs and revenue momentum. New units typically require several quarters to reach steady-state utilization, resulting in startup expense that can weigh on EBIT in the early ramp. Evidence that recent openings are moving through the ramp curve on schedule would support the 75.96 million US‑dollar EBIT run-rate implied by forecasts; delays or lower‑than‑planned throughput would raise the risk that adjusted EPS remains toward the low end of the company’s guidance band. Guidance commentary around capital deployment priorities and the timing of additional capacity activations will shape how investors handicap second‑quarter and full‑year trajectories.

Analyst Opinions

Bullish views dominate recent commentary, with a clear majority of firms expressing positive stances versus neutral perspectives. Several well-known institutions highlight improving execution and embedded earnings power, while acknowledging the near-term expense headwinds that have pressured bottom-line metrics. RBC has reiterated an Outperform stance and raised its price target in recent months, emphasizing the company’s capacity-driven growth and the potential for accelerating free cash flow as unit-level economics normalize. Their thesis centers on continued bed additions, solid demand across inpatient and residential settings, and a path to better operating leverage once cost pressures abate. UBS has maintained a Buy rating while lifting its target, pointing to a favorable setup for revenue growth and the opportunity for margin recapture from efficiency gains and reduced reliance on premium labor, alongside disciplined capital allocation to the most accretive projects. TD Cowen also maintains a Buy outlook, underscoring improving operational discipline under the current leadership and the presence of “embedded” EBITDA growth from facilities that were opened or expanded in the prior periods and are still ramping toward steady-state volumes. This lens frames the current quarter as a checkpoint on conversion—if revenue lands in the midpoint of the 820–830 million US‑dollar range and EBIT approaches the 75.96 million US‑dollar consensus, the debate shifts to how quickly adjusted EPS can re‑align with top‑line growth as the company cycles past elevated non-operating and liability‑related costs. Synthesizing the bullish majority view, the setup for the quarter is balanced by top-line resilience and cost uncertainty, yet constructive on the medium-term. Supportive demand for acute and residential behavioral services underpins revenue visibility, while a robust pipeline of bed additions points to ongoing volume-led growth. The bulls are effectively betting that last quarter’s large GAAP loss is not indicative of ongoing earnings power and that improved cost control—particularly around liability and labor—should close the gap between revenue growth of 6.89% and the currently modeled 25.44% year-over-year decline in adjusted EPS. If early signs of expense normalization emerge in this print, analysts expect the stock to recalibrate toward EBIT and cash flow momentum rather than headline GAAP noise.